NCT03165955View on ClinicalTrials.gov

A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 9, 2017

Primary Completion Date

November 22, 2018

Study Completion Date

November 22, 2018

Conditions
Breastcancer
Interventions
DRUG

Oraxol

HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules

Trial Locations (6)

110

Taipei Medical University Hospital, Taipei

114

Tri-Service General Hospital, Taipei

10048

National Taiwan University Hospital, Taipei

11217

Taipei Veterans Generla Hospital, Taipei

23561

Shuang Ho Hospital, Taipei

40447

China Medical University Hospital, Taichung

Sponsors

Lead Sponsor

Health Hope Pharma

Collaborators (1)

PharmaEssentia
All Listed Sponsors
collaborator

PharmaEssentia

INDUSTRY

lead

Health Hope Pharma

INDUSTRY

NCT03165955 - A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients | Biotech Hunter | Biotech Hunter